Neurocrine Bio's NBI-98854 misses endpoint at low dose, higher dose shows promise


Neurocrine Biosciences (NBIX) plunges 29% AH as the 50mg dose of the small molecule VMAT2 inhibitor NBI-98854 misses the primary endpoint in a Phase 2b tardive dyskinesia study.

A 100mg dose (which the company apparently thought would be the maximum tolerated dose but turned out to be well tolerated in the study) did produce a statistically significant reduction in tardive dyskinesia symptoms.

The company decides to do the logical thing given the results: "We will now perform an additional Phase 2 study utilizing 100mg and higher doses." (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs